This study reveals a synergistic antitumor mechanism by which dual inhibition of integrin and CD47 pathways remodels the tumor microenvironment, offering novel insights for overcoming enzalutamide resistance and treating bone-metastatic prostate cancer. It particularly highlights the experimental design strategy of co-targeting microenvironmental signals and immune escape pathways.
Literature Overview
This paper, 'An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape,' published in the journal Molecular Cancer, systematically investigates the multi-target antitumor effects of a novel oral integrin antagonist, C19-9N, in castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC). The study not only validates C19-9N's inhibition of tumor cell-autonomous signaling but also reveals its ability to reprogram the immune microenvironment by modulating tumor-associated macrophage (TAM) polarization and blocking the CD47 'don't eat me' signal. This mechanism provides a new avenue for overcoming therapeutic resistance and bone metastasis.Background Knowledge
Currently, advanced prostate cancer, particularly enzalutamide-resistant bone-metastatic CRPC and NEPC, remains a significant clinical challenge. These subtypes exhibit high heterogeneity and are often accompanied by treatment resistance and immune escape, leading to poor patient prognosis. Although AR signaling remains a core driver, expression of the AR splice variant AR-V7 renders tumors resistant to anti-androgen therapies like enzalutamide. Simultaneously, immunosuppressive TAMs and high CD47 expression in the tumor microenvironment (TME) further promote immune escape, forming a dual resistance barrier. Existing targeted therapies mostly focus on single pathways, making it difficult to overcome functional redundancy and compensatory activation among integrin subtypes. For example, inhibiting αvβ3 often triggers compensatory upregulation of α5β1 or αvβ5, limiting efficacy. Therefore, developing bifunctional drugs that simultaneously target oncogenic signaling within tumor cells and immune escape in the TME has become a key strategy to overcome this bottleneck. This study, based on an in-depth understanding of the multifaceted roles of the integrin family in prostate cancer progression, proposes a co-targeting strategy for pan-αv and α5β1 to block the extracellular matrix (ECM)-integrin signaling axis, thereby simultaneously interfering with stemness, EMT, and immune escape.
Research Methods and Experiments
The research team first confirmed high expression of αv and α5 in mCRPC and NEPC through immunohistochemistry and Western blot analysis of various prostate cancer tissues and cell lines, revealing partial complementarity. Building on the previously developed C19-9 molecule, they optimized it by introducing a nitrogen-containing heterocyclic structure to obtain the novel orally bioavailable pan-αv/α5β1 antagonist C19-9N. Using surface plasmon resonance (SPR), microscale thermophoresis (MST), and molecular docking techniques, they verified C19-9N's high-affinity binding to αvβ3, αvβ5, αvβ6, αvβ8, and α5β1, independent of Mn²⁺, thus avoiding the reverse pro-adhesive effects of traditional RGD agonists. In vitro, using cell lines such as 22RV1, PC3, and NCI-H660, they systematically evaluated the effects of C19-9N on proliferation, migration, stemness, and EMT through CCK-8, Transwell, and sphere formation assays. In vivo, they constructed multiple models, including subcutaneous xenografts, bone metastasis models (via intracardiac or intratibial injection), NEPC patient-derived PDX models, and immunocompetent MycCaP-Bo bone metastasis models, to comprehensively assess the monotherapy and combination efficacy of C19-9N. Mechanistically, they analyzed changes in the TME immune landscape using single-cell RNA sequencing (scRNA-seq), and validated immune regulatory functions using multiplex immunofluorescence and bone marrow-derived macrophage (BMDM) phagocytosis assays.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a novel small-molecule template for drug development—one that combines targeting intracellular tumor signals with reprogramming the immune microenvironment. The oral bioavailability and favorable safety profile of C19-9N greatly enhance its clinical translatability, especially for long-term management of patients with bone metastases. Its indirect modulation of CD47 avoids the hematologic toxicity risks associated with anti-CD47 antibodies, potentially serving as a safer immune checkpoint intervention.
In terms of clinical monitoring, the study suggests that integrin expression profiles and AR-V7 levels could serve as predictive biomarkers for C19-9N efficacy, supporting personalized treatment strategies. Additionally, TAM polarization status and CD8+ T cell infiltration levels could be used as dynamic pharmacodynamic monitoring indicators.
For disease modeling, the NEPC PDX and immunocompetent bone metastasis models used in this study provide reliable platforms for evaluating novel integrin-targeted therapeutics, emphasizing the need to validate efficacy in models with greater clinical relevance.
Conclusion
This study systematically reveals the multi-dimensional antitumor mechanisms of the oral integrin antagonist C19-9N in aggressive prostate cancer. It not only overcomes enzalutamide resistance by inhibiting PI3K/AKT and STAT3 pathways to block AR-V7 splicing but also activates innate immune responses by remodeling the tumor microenvironment, promoting TAM polarization, and downregulating CD47. This dual strategy—targeting both tumor cells and immune escape—provides a novel paradigm for treating advanced prostate cancer, particularly CRPC and NEPC. With high oral bioavailability and a favorable safety profile, C19-9N emerges as a highly promising clinical candidate. Future research should focus on its broad-spectrum potential in other integrin-dependent cancers and explore its combination potential with existing immune checkpoint inhibitors. This work not only advances the optimization of integrin-targeted therapeutics but also provides an important reference for developing dual-function small molecules that combine signal suppression with immune activation, potentially serving as a cornerstone treatment strategy to improve patient outcomes.
